Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s treatment for classic galactosemia.

The Trump administration may also be more aggressive targeting specific sectors, such as pharmacy benefit managers. Although ...

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the ...

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...